rupiya.io
⠋Loading...
0%
❯ Evaluating quality metrics...
Ipca Laboratories Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Ipca Laboratories Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | FY25 | FY24 | FY23 | FY22 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹8,855 Cr | ₹7,622 Cr | ₹6,207 Cr | |||||||||||||
| Expenses | ₹7,499 Cr | ₹6,688 Cr | ₹5,502 Cr | |||||||||||||
| Operating Profit | ₹1,356 Cr | ₹934 Cr | ₹705 Cr | |||||||||||||
| OPM % | 15.3% | 12.3% | 11.4% | |||||||||||||
| Other Income | ₹8 Cr | ₹7 Cr | ₹15 Cr | |||||||||||||
| Depreciation | ₹398 Cr | ₹357 Cr | ₹262 Cr | |||||||||||||
| Interest | ₹84 Cr | ₹137 Cr | ₹45 Cr | |||||||||||||
| Profit Before Tax | ₹1,131 Cr | ₹843 Cr | ₹745 Cr | |||||||||||||
| Tax | ₹344 Cr | ₹313 Cr | ₹253 Cr | |||||||||||||
| Net Profit | ₹738 Cr | ₹547 Cr | ₹471 Cr | |||||||||||||
| EPS (₹) | 29.1 | 21.6 | 18.6 | |||||||||||||
| Dividend Payout % | 0% | 0% | 0% |
Register free to see 13 more years.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,546 Cr | ₹1,512 Cr | ₹1,585 Cr | ₹2,034 Cr | ||||||||
| Expenses | ₹1,330 Cr | ₹1,331 Cr | ₹1,278 Cr | ₹1,673 Cr | ||||||||
| Operating Profit | ₹216 Cr | ₹181 Cr | ₹308 Cr | ₹361 Cr | ||||||||
| OPM % | 14.0% | 12.0% | 19.0% | 18.0% | ||||||||
| Depreciation | ₹67 Cr | ₹70 Cr | ₹69 Cr | ₹90 Cr | ||||||||
| Interest | ₹11 Cr | ₹18 Cr | ₹31 Cr | ₹44 Cr | ||||||||
| Net Profit | ₹110 Cr | ₹78 Cr | ₹164 Cr | ₹136 Cr | ||||||||
| EPS (₹) | 4.3 | 3.0 | 6.4 | 5.7 |
Register free to see 8 more quarters.
| Period | FY25 | FY24 | FY23 | FY22 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹25 Cr | ₹25 Cr | ₹25 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹5,531 Cr | ₹4,899 Cr | ₹4,404 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹1,363 Cr | ₹1,438 Cr | ₹1,481 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹2,010 Cr | ₹1,936 Cr | ₹1,230 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹3,372 Cr | ₹3,374 Cr | ₹2,711 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹4,763 Cr | ₹4,696 Cr | ₹2,732 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹191 Cr | ₹285 Cr | ₹277 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | ₹1,874 Cr | ₹1,687 Cr | ₹989 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | ₹2,560 Cr | ₹2,471 Cr | ₹1,743 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | ₹167 Cr | ₹209 Cr | ₹1,258 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹2,206 Cr | ₹1,754 Cr | ₹1,627 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹11,761 Cr | ₹11,101 Cr | ₹8,626 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 13 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY25 | ₹1,321 Cr | ₹-870 Cr | ₹-283 Cr | ₹169 Cr |
| FY24 | ₹945 Cr | ₹-1,292 Cr | ₹-553 Cr | ₹-900 Cr |
| FY23 | ₹806 Cr | ₹-725 Cr | ₹507 Cr | ₹588 Cr |
| FY22 | ||||
| Mar 2015 | ||||
| Mar 2016 | ||||
| Mar 2017 | ||||
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 |
Register free to see 13 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.